Drug intelligence / Profile preview

gw003

Development stage: Phase 1
Lead developer: Mabwell
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

GW003 is a biosimilar of balugrastim, developed as a granulocyte colony-stimulating factor (G-CSF) stimulant. It is designed to stimulate the production of neutrophils and reduce the incidence of neutropenia in patients undergoing chemotherapy. GW003 is administered via subcutaneous injection and has been evaluated for safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in both healthy subjects and patients with breast cancer[1][2][4][9][10]. The drug is being developed by Mabwell (Shanghai) Biosci and Jiangsu T-Mab Biopharma Co.,Ltd.

Other names: GW003GW-003GW 003balugrastim biosimilar

Targets

CSF3R (Granulocyte colony-stimulating factor receptor)

Beyond the preview

Go deeper on gw003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gw003.

Explore the full profile